4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to 4D Molecular Therapeutics webcast presentation of Interim Safety and Efficacy Data from the Phase 1 AEROW Clinical Trial of Aerosolized 4D-710 in patients with Cystic Fibrosis Lung Disease. (Operator Instructions). As a reminder, today's call is being recorded.
With that, I will hand the call over to August Moretti, Chief Financial Officer, who will make introductory comments.
Thank you, operator, and welcome, everyone, to 4D Molecular Therapeutics' 4D-710 interim data webcast. A press release describing the results and development plans related to 4D-710 is accessible in the Investors section of the 4D Molecular Therapeutics website, and a recording of this webcast will be accessible on our website after completion of this call.
With me today are: Dr. David Kirn, our Co-Founder and Chief Executive Officer; and Dr. Jennifer Taylor-Cousar, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |